SBI Securities’s Astria Therapeutics ATXS Stock Holding History

SBI Securities’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$13	–	4031
2025 Q4	$13	Sell	1 -2	-67%	-$24	﹤0.01%	3841
2025 Q3	$22	Buy	3 +2	+200%	+$14	﹤0.01%	3893
2025 Q2	$5	Hold	1	–	–	﹤0.01%	4063
2025 Q1	$5	Hold	1	–	–	﹤0.01%	4030
2024 Q4	$9	Buy	+1	New	+$11	﹤0.01%	3937

SBI Securities's ATXS Position: Q1 2026 in Review

SBI Securities sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1 share — an estimated $13 sold.

SBI Securities first reported a position in ATXS in Q4 2024 and held it in 5 quarters. The position peaked at $22 in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

SBI Securities reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
SBI Securities sold 1 Astria Therapeutics share in Q1 2026, an estimated $13.
SBI Securities first reported a position in Astria Therapeutics in Q4 2024 and held it in 5 quarters.
SBI Securities's Astria Therapeutics position peaked at $22 in Q3 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.